BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating) CFO Troy Wichterman sold 1,576 shares of the firm’s stock in a transaction dated Wednesday, March 1st. The stock was sold at an average price of $22.75, for a total value of $35,854.00. Following the sale, the chief financial officer now directly owns 77,253 shares of the company’s stock, valued at $1,757,505.75. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Troy Wichterman also recently made the following trade(s):
- On Tuesday, February 21st, Troy Wichterman sold 117 shares of BioLife Solutions stock. The stock was sold at an average price of $21.47, for a total value of $2,511.99.
- On Thursday, December 22nd, Troy Wichterman sold 528 shares of BioLife Solutions stock. The stock was sold at an average price of $17.55, for a total value of $9,266.40.
BioLife Solutions Stock Performance
NASDAQ BLFS opened at $23.93 on Monday. The company has a market cap of $1.02 billion, a P/E ratio of -9.65 and a beta of 1.86. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.68 and a quick ratio of 2.76. The stock has a 50-day moving average of $22.40 and a two-hundred day moving average of $22.07. BioLife Solutions, Inc. has a 1-year low of $10.40 and a 1-year high of $26.96.
Wall Street Analyst Weigh In
Hedge Funds Weigh In On BioLife Solutions
Several hedge funds and other institutional investors have recently made changes to their positions in BLFS. BlackRock Inc. boosted its stake in shares of BioLife Solutions by 10.7% in the 3rd quarter. BlackRock Inc. now owns 5,416,115 shares of the medical equipment provider’s stock valued at $123,217,000 after buying an additional 522,912 shares during the period. Millennium Management LLC boosted its stake in shares of BioLife Solutions by 45.3% in the 2nd quarter. Millennium Management LLC now owns 1,560,137 shares of the medical equipment provider’s stock valued at $21,545,000 after buying an additional 486,631 shares during the period. Jennison Associates LLC boosted its stake in shares of BioLife Solutions by 64.6% in the 4th quarter. Jennison Associates LLC now owns 993,239 shares of the medical equipment provider’s stock valued at $18,077,000 after buying an additional 389,812 shares during the period. Fred Alger Management LLC boosted its stake in shares of BioLife Solutions by 21.9% in the 3rd quarter. Fred Alger Management LLC now owns 2,163,476 shares of the medical equipment provider’s stock valued at $49,219,000 after buying an additional 388,642 shares during the period. Finally, Bessemer Group Inc. purchased a new position in shares of BioLife Solutions in the 3rd quarter valued at about $8,673,000. Hedge funds and other institutional investors own 89.82% of the company’s stock.
About BioLife Solutions
BioLife Solutions, Inc engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services.
- Get a free copy of the StockNews.com research report on BioLife Solutions (BLFS)
- MarketBeat Week in Review – 2/27 – 3/3
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.